Skip to main content
SpringerLink
Log in

Neutropenic Fever and Sepsis: Evaluation and Management

  • Chapter
  • First Online:
Infectious Complications in Cancer Patients

Part of the book series: Cancer Treatment and Research ((CTAR,volume 161))

Abstract

Neutropenia remains the predominant predisposing factor for infection in most cancer patients. Bacterial and fungal infections are common in this setting. Not all neutropenic patients have the same risk of developing severe infection or serious medical complications. Although all patients with neutropenia and fever should receive prompt, empiric antibiotic therapy, low-risk patients can be effectively managed without hospitalization—often with the administration of oral antibiotics. Other patients need hospital-based therapy. The emergence of resistant microorganisms has become a significant problem in neutropenic patients. Frequent epidemiologic surveys to detect the emergence of resistant organisms are recommended. Antibiotic stewardship and Infection Control Programs are important tools in combating resistant organisms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bodey GP, Buckley M, Sathe YS et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340

    Article  PubMed  CAS  Google Scholar 

  2. Freifeld AG, Bow EJ, Sepkowicz KA et al (2011) Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52:e56–e93

    Article  PubMed  Google Scholar 

  3. Bodey GP, Fainstein V, Elting LS et al (1990) Beta-lactam regimens for the febrile neutropenic patient. Cancer 65:9–16

    Article  PubMed  CAS  Google Scholar 

  4. Rolston KVI (2003) Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev 29:551–554

    Article  PubMed  Google Scholar 

  5. Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S32–S37

    Article  PubMed  Google Scholar 

  6. Greene RE, Schlamm HT, Oestmann JW et al (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44:373–379

    Article  PubMed  Google Scholar 

  7. Wheat LJ, Walsh TJ (2008) Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 27:245–251

    Article  PubMed  CAS  Google Scholar 

  8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Speilberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis 48(1):1–12

    Article  PubMed  Google Scholar 

  9. Talbot GH, Bradley J, Edwards JE Jr et al (2006) Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis 42:657–668

    Article  PubMed  Google Scholar 

  10. Dellit TH, Owens RC, McGowan JE et al (2007) Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177

    Article  PubMed  Google Scholar 

  11. Paskovaty A, Pflomm JM, Myke N et al (2005) A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int J Antimicrob Agents 25:1–10

    Article  PubMed  CAS  Google Scholar 

  12. Diekema DJ, Jones RN, Rolston KVI (1999) Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers. Diagn Microbiol Infect Dis 34:37–43

    Article  PubMed  CAS  Google Scholar 

  13. Rolston KVI, Kontoyiannis DP, Yadegarynia D et al (2005) Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diag Microbiol Infect Dis 51:215–218

    Article  CAS  Google Scholar 

  14. Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494

    Article  PubMed  CAS  Google Scholar 

  15. Jacobson K, Rolston K, Elting L et al (1999) Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 45:325–334

    Article  PubMed  CAS  Google Scholar 

  16. Wisplinghoff H, Seifert H, Wenzel RP et al (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110

    Article  PubMed  Google Scholar 

  17. Yadegarynia D, Tarrand J, Raad I (2003) Current spectrum of bacterial infections in cancer patients. Clin Infect Dis 37:1144–1145

    Article  PubMed  CAS  Google Scholar 

  18. Rolston KVI, Bodey GP (2006) Infections in patients with cancer. In: Kufe DW, Bast RC Jr, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E III (eds) Cancer medicine, e7. BC Decker, Hamilton, Ontario, pp 2222–2245

    Google Scholar 

  19. Elting LS, Bodey GP, Fainstein V (1986) Polymicrobial septicemia in the cancer patient. Medicine 65:218–225

    Article  PubMed  CAS  Google Scholar 

  20. Rolston KVI, Bodey GP, Safdar A (2007) Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 45:228–233

    Article  PubMed  Google Scholar 

  21. Adachi JA, Yadegarynia D, Rolston K (2003) Spectrum of polymicrobial bacterial infection in patients with cancer, 1975–2002. (Abstract 4) In: American Society for Microbiology. Polymicrobial diseases, Lake Tahoe, NV, Oct. 19–23

    Google Scholar 

  22. Rolston KVI, Tarrand JJ (1999) Pseudomonas aeruginosa—Still a frequent pathogen in patients with cancer: 11-year experience from a comprehensive cancer center. Clin Infect Dis 29:463–464

    Article  PubMed  CAS  Google Scholar 

  23. Safdar A, Rolston KV (2007) Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 45:1602–1609

    Article  PubMed  Google Scholar 

  24. Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the twentyfirst Century. Cancer 103:1103–1113

    Article  PubMed  Google Scholar 

  25. Fainstein V, Elting LS, Bodey GP (1989) Bacteremia caused by non-sporulating anaerobes in cancer patients A 12 year experience. Medicine 68:151–162

    Article  PubMed  CAS  Google Scholar 

  26. Gifford AH, Kirkland KB (2006) Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 25:751–755

    Article  PubMed  CAS  Google Scholar 

  27. Han XY, Dé I, Jacobson KL (2007) Rapidly growing mycobacteria clinical and microbiologic studies of 115 cases. Am J Clin Pathol 128:612–621

    Article  PubMed  Google Scholar 

  28. Abi-Said D, Anaissie E, Uzun O et al (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122–1128

    Article  PubMed  CAS  Google Scholar 

  29. Hachem R, Hanna H, Kontoyiannis D et al (2008) The changing epidemiology of invasive candidiasis. Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493–2499

    Article  PubMed  Google Scholar 

  30. Horn DL, Neofytos D, Anaissie E et al (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48:1695–1703

    Article  PubMed  CAS  Google Scholar 

  31. Wingard JR, Merz WG, Rinaldi MC et al (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277

    Article  PubMed  CAS  Google Scholar 

  32. Mullen CA, Abd El-Baki H, Samir H et al (2003) Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer 11:321–325

    PubMed  CAS  Google Scholar 

  33. Chamilos G, Luna M, Lewis RE et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91:986–989

    PubMed  Google Scholar 

  34. Patterson TF, Kirkpatrick WR, White M et al (2000) Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 79:250–260

    Article  PubMed  CAS  Google Scholar 

  35. Trifilio SM, Bennett CL, Yarnold PR et al (2007) Breakthrough zygomycosis after voriconazole administration among patients with hematolgic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39:425–429

    Article  PubMed  CAS  Google Scholar 

  36. Marty FM, Cosimi LA, Baden LR (2004) Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350:950–952

    Article  PubMed  CAS  Google Scholar 

  37. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al (2004) Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect DIs 39:584–587

    Article  PubMed  Google Scholar 

  38. Kontoyiannis DP, Wessel VC, Bodey GP et al (2000) Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 30:851–856

    Article  PubMed  CAS  Google Scholar 

  39. Khanna N, Widmer AF, Decker M et al (2008) Respiratory syncytial virus infection in patients with hematological diseases: Single-center study and review of the literature. Clin Infect Dis 46:402–412

    Article  PubMed  CAS  Google Scholar 

  40. Cooksley CD, Avritscher EBC, Bekele BN et al (2005) Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 104:618–628

    Article  PubMed  Google Scholar 

  41. Klastersky J, Paesmans M, Rubenstein E et al (2000) The MASCC risk index: a multinational scoring system to predict low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051

    PubMed  CAS  Google Scholar 

  42. Santolaya ME, Alvarez AM, Avilés CL et al (2002) Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis 35:678–683

    Article  PubMed  CAS  Google Scholar 

  43. Freifeld A, Marchigiani D, Walsh T et al (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311

    Article  PubMed  CAS  Google Scholar 

  44. Kern WV, Cometta A, De Bock R et al (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341:312–318 International antimicrobial therapy cooperative group of the European organization for research and treatment of cancer

    Article  PubMed  CAS  Google Scholar 

  45. Rolston K (1999) New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29:515–521

    Article  PubMed  CAS  Google Scholar 

  46. Bodey GP, Grose WE, Keating MJ (1982) Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis 4:579–585

    Article  PubMed  CAS  Google Scholar 

  47. Haron E, Rolston KVI, Cunningham C et al (1989) Oral ciprofloxacin therapy for infections in cancer patients. J Antimicrob Chemother 24:955–962

    Article  PubMed  CAS  Google Scholar 

  48. Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561–2568

    Article  PubMed  CAS  Google Scholar 

  49. Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114

    PubMed  CAS  Google Scholar 

  50. Innes HE, Smith DB, O’Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer 89:43–49

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  51. Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134

    Article  PubMed  CAS  Google Scholar 

  52. Santolaya ME, Alvarez AM, Avilés CL et al (2004) Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22:3784–3789

    Article  PubMed  Google Scholar 

  53. Rubenstein EB, Rolston K, Benjamin RS et al (1993) Outpatient treatment of febrile episodes in low risk neutropenic cancer patients. Cancer 71:3640–3646

    Article  PubMed  CAS  Google Scholar 

  54. Rolston K, Rubenstein E, Elting L et al (1995) Ambulatory management of febrile episodes in low-risk neutropenic patients [abstract LM81]. In: program and abstract of the 35th interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, Washington, DC

    Google Scholar 

  55. Mullen CA, Petropoulos D, Roberts WM et al (1999) Outpatient treatment of febrile neutropenia in low risk pediatric cancer patients. Cancer 86:126–134

    Article  PubMed  CAS  Google Scholar 

  56. Rolston KVI, Manzullo EF, Elting LS et al (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia. Cancer 106:2489–2494

    Article  PubMed  CAS  Google Scholar 

  57. Rolston KVI, Frisbee-Hume SE, Patel S et al (2009) Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18(1):89–94

    Article  PubMed  Google Scholar 

  58. Elting LS, Lu C, Escalante CP et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611

    Article  PubMed  Google Scholar 

  59. Escalante CP, Weiser MA, Manzullo E et al (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12:657–662

    PubMed  Google Scholar 

  60. Hidalgo M, Hornedo J, Lumbreras JM et al (1999) Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. Cancer 85:213–219

    Article  PubMed  CAS  Google Scholar 

  61. Vidal L, Paul M, Ben dor I et al (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 54:29–37

    Article  PubMed  CAS  Google Scholar 

  62. Kern KV (2006) Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 15:533–540

    Article  Google Scholar 

  63. Rolston KVI (2004) The infectious diseases society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 39(Suppl 1):S44–S48

    Article  PubMed  Google Scholar 

  64. Rolston KVI, Nguyen H, Amos G et al (1994) A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 69:350–355

    Article  Google Scholar 

  65. Jaksic B, Martinelli G, Perez-Oteyza J et al (2006) Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42:597–607

    Article  PubMed  CAS  Google Scholar 

  66. Cinetta A, Kern WV, De Bock R et al (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37:382–389

    Article  Google Scholar 

  67. Rubin M, Hathorn JW, Marshall D et al (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30–35

    Article  PubMed  CAS  Google Scholar 

  68. Ramphal R, Bolger M, Oblon DJ et al (2003) Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36:1062–1067

    Article  Google Scholar 

  69. Segal BH, Freifeld AG, Baden LR et al (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6:122–174

    PubMed  Google Scholar 

  70. Pizzo PA, Hathorn JW, Hiemenez J et al (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552–558

    Article  PubMed  CAS  Google Scholar 

  71. Rolston K, Berkey P, Bodey GP et al (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283–291

    Article  PubMed  CAS  Google Scholar 

  72. Behre G, Link H, Maschmeyer G et al (1998) Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 76:73–80

    Article  PubMed  CAS  Google Scholar 

  73. Cometta A, Calandra T, Gaya H et al (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The international antimicrobial therapy cooperative group of the European organization for research and treatment of cancer and the gruppo italiano malattie ematologiche maligne dell’adulto infection program. Antimicrob Agents Chemother 40:1108–1115

    PubMed Central  PubMed  CAS  Google Scholar 

  74. Akova M, Akan H, Korten V et al (1999) Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomized multicentre trial in patients without previous prophylactic antibiotics. Meropenem study group of Turkey. Int J Antimicrob Agents 13:15–19

    Article  PubMed  CAS  Google Scholar 

  75. Yamamura D, Gucalp R, Carlisle P et al (1997) Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 41:1704–1708

    PubMed Central  PubMed  CAS  Google Scholar 

  76. Del Favero A, Menichette F, Martino P et al (2001) A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33:1295–1301

    Article  PubMed  Google Scholar 

  77. Raad II, Abi-Said D, Rolston KV et al (1998) How should imipenem-cilistatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer 82:2449–2458

    Article  PubMed  CAS  Google Scholar 

  78. Feld R, DePauw B, Berman S et al (2000) Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 18:3690–3698

    PubMed  CAS  Google Scholar 

  79. Paul M, Soares-Weiser K, Leibovici L (2003) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Brit Med J 326:1111–1119

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  80. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L (2007) Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 7:338–348

    Article  PubMed  CAS  Google Scholar 

  81. Rolston KVI, Kontoyiannis DP, Raad II, LeBlanc BJ, Streeter HL, Ho DH (2003) Susceptibility surveillance among gram-negative bacilli at a comprehensive cancer center (Abstract A-004). In: 103rd general meeting American Society of Microbiology. Washington, D.C., May 18–22

    Google Scholar 

  82. Rolston KVI, Bodey GP (2006) Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 58:478

    Article  PubMed  CAS  Google Scholar 

  83. Glasmacher A, von Lilienfled-Toal M, Schulte S et al (2005) An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 11(Suppl 5):17–23

    Article  PubMed  CAS  Google Scholar 

  84. Kim PW, Wu YT, Cooper C, Rochester G, Valappil T, Wang Y, Kornegay C, Nambiar S (2010) Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51(4):381–389

    Article  PubMed  Google Scholar 

  85. Elting LS, Rubenstein EB, Rolston K et al (2000) Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 18:3699–3706

    PubMed  CAS  Google Scholar 

  86. Pizzo PA, Robichard KJ, Gill FA (1979) Duration of empiric antibiotic therapy in granulopenic patients with cancer. Am J Med 67:194–199

    Article  PubMed  CAS  Google Scholar 

  87. Corey L, Boeckh M (2002) Persistent fever in patients with neutropenia. N Engl J Med 346:222–224

    Article  PubMed  Google Scholar 

  88. Smith TH, Khatcheressian J, Lyman GH et al (2006) 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205

    Article  PubMed  CAS  Google Scholar 

  89. Hübel K, Carter RA, Liles WC et al (2002) Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 42:1414–1421

    Article  PubMed  Google Scholar 

  90. Price TH, Bowden RA, Boeckh M et al (2000) PhaseI/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95:3302–3309

    PubMed  CAS  Google Scholar 

  91. Gafter-Gvili A, Fraser A, Paul M et al (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995

    Article  PubMed  Google Scholar 

  92. Segal BH, Freifeld AG (2007) Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Cancer Netw 5:235–242

    CAS  Google Scholar 

  93. Kern WV, Andriof E, Oethinger M et al (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  94. Baden LR (2005) Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353:1052–1054

    Article  PubMed  CAS  Google Scholar 

  95. Green H, Paul M, Vidal L et al (2007) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients (review). Cochrane Database Syst Rev 3, Art No.: CD005590

    Google Scholar 

  96. Hamza NS, Ghannoum MA, Lazarus HM (2004) Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transpl 34:377–389

    Article  CAS  Google Scholar 

  97. van Burik JAH (2005) Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 18:479–483

    Article  PubMed  Google Scholar 

  98. van Burik JAH, Ratanatharathorn V, Stepan DE et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407–1416

    Article  PubMed  Google Scholar 

  99. Cordonnier C, Maury S, Pautas C et al (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transpl 33:943–948

    Article  CAS  Google Scholar 

  100. DePauw BE, Donnelly JP (2007) Prophylaxis and aspergillosis—has the principle been proven? N Engl J Med 356:409–411

    Article  CAS  Google Scholar 

  101. Metjian TA, Prasad PA, Kogon A et al (2008) Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. Pediatr Infect Dis J 27:106–111

    PubMed  Google Scholar 

  102. Agwu A, Lee CKK, Jain SK et al (2008) A worldwide web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis 47:747–753

    Article  PubMed  Google Scholar 

  103. Mulanovich V, Chemaly R, Mihu C et al (2009) Antimicrobial stewardship program in the critical care unit (CcU) of a comprehensive cancer center. (Abst. 09-070). Multinational Association for Supportive Care in Cancer 2009 International MASCC/ISOO Symposium Rome, Italy, June 25–27

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Infection Control, and Employee Health, V.T. MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA

    Kenneth V. I. Rolston

Authors
  1. Kenneth V. I. Rolston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth V. I. Rolston .

Editor information

Editors and Affiliations

  1. Div. Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Valentina Stosor

  2. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Teresa R. Zembower

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Rolston, K.V.I. (2014). Neutropenic Fever and Sepsis: Evaluation and Management. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham. https://doi.org/10.1007/978-3-319-04220-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-04220-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-04219-0

  • Online ISBN: 978-3-319-04220-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation